BUZZ-Revvity falls on forecasting 2025 revenue, profit below estimates

Reuters01-31 23:04
BUZZ-Revvity falls on forecasting 2025 revenue, profit below estimates

** Shares of medical equipment maker Revvity RVTY.N fall 2.4% to $123.75

** Co forecast 2025 profit and revenue below estimates

** Co forecast 2025 adj. profit to be in the range of $4.90 to $5.00 per share, compared with analysts' estimates of $4.99, as per data compiled by LSEG

** Forecast 2025 revenue to be in the range of $2.80 bln to $2.85 bln, lower than estimates of $2.87 bln

** RVTY was expected to forecast lower with both Danaher DHR.N and Thermo Fisher TMO.N guiding lower vs. the Street expectations, brokerage Leerink Partners says

** Adds, "thus we see limited downside surprise" as the outlook is still 4% organic growth at the midpoint, which is higher vs. peers so far

** Co, however, beats Q4 profit and revenue estimates on strong sales in its life sciences and diagnostics units

** Reports Q4 adj. profit of $1.42 per share vs estimates of $1.37 per share

** Stock had risen 2.1% in 2024

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment